Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nab-paclitaxel Plus Gemcitabine · 1 trial · 1 indication
Duration from the date of initial treatment to the date of death due to any cause
| Arm | Type | Description |
|---|---|---|
| Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine | EXPERIMENTAL | - |
| Nab-paclitaxel Plus Gemcitabine | ACTIVE_COMPARATOR | - |
| Surufatinib with Nab-paclitaxel, and Gemcitabine | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine | DRUG | Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine 1. Surufatinib: 200mg, qd 2. Camrelizumab: 200mg, IV drip, Q3W, D1 3. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8 4. Gemcitabine : 1000 mg/m2, IV drip, D1, D8 |
| Nab-paclitaxel Plus Gemcitabine | DRUG | Drug: Nab-paclitaxel Plus Gemcitabine 1. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8 2. Gemcitabine : 1000 mg/m2, IV drip, D1, D8 |
| Surufatinib with Nab-paclitaxel, and Gemcitabine | DRUG | Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine 1. Surufatinib: 200mg, qd 2. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8 3. Gemcitabine : 1000 mg/m2, IV drip, D1, D8 |
Inclusion Criteria: 1. Fully understand and voluntarily sign an informed consent form, willing and able to follow the study process; 2. Age range is 18-75 years old (inclusive); 3. Pancreatic cancer confirmed by histology or cytology; 4. Stage IV metastasis Pancreatic cancer patients; 5. Have not r...
Top 20 of 67 competitors
Nab-paclitaxel Plus Gemcitabine is a combination regimen being studied for the treatment of metastatic pancreatic cancer. It is part of an investigational therapy that also includes surufatinib and camrelizumab. The regimen is currently being evaluated in a Phase II/III clinical trial in China.
Nab-paclitaxel Plus Gemcitabine is being developed by HUTCHMED (China) Limited, a biopharmaceutical company listed on the stock exchange under the ticker HCM. The company is conducting a clinical trial of this combination regimen for metastatic pancreatic cancer.
Nab-paclitaxel Plus Gemcitabine is in Phase 2 of clinical development. It is being studied in a Phase II/III trial, and the trial is currently recruiting participants. The drug combination is investigational and has not been approved for use.
Nab-paclitaxel Plus Gemcitabine is being studied in a single clinical trial with the identifier NCT06361888. This Phase II/III trial evaluates the efficacy and safety of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine in metastatic pancreatic cancer. The trial is recruiting 502 participants in China.
Nab-paclitaxel Plus Gemcitabine is a component of the combination therapy being tested in the clinical trial NCT06361888. The full regimen includes surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine. Nab-paclitaxel and gemcitabine are the chemotherapy backbone of this investigational combination.